Who are Tofacitinib with methotrexate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tofacitinib-with-methotrexate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tofacitinib with methotrexate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tofacitinib with methotrexate (Tofacitinib with methotrexate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor + DMARD. Area: Immunology.

marketed JAK inhibitor + DMARD JAK1, JAK3 (tofacitinib); dihydrofolate reductase (methotrexate) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Tofacitinib with methotrexate (Tofacitinib with methotrexate) — Pfizer. Tofacitinib inhibits Janus kinase (JAK) enzymes to suppress inflammatory cytokine signaling, while methotrexate provides additional immunosuppression through antifolate activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tofacitinib with methotrexate TARGET	Tofacitinib with methotrexate	Pfizer	marketed	JAK inhibitor + DMARD	JAK1, JAK3 (tofacitinib); dihydrofolate reductase (methotrexate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor + DMARD class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tofacitinib with methotrexate — Competitive Intelligence Brief. https://druglandscape.com/ci/tofacitinib-with-methotrexate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing